Moreover, HER2 is known to be related to rapid growth of tumours, and might be a good marker to add to the Surr-INVIGOR; however, our study cohort was overwhelmingly HER2 negative and thus its impact within a prognostic model could not be properly measured. This evidence concerns the gene ERBB2 and neoplasm.